Biopharmaceutical company Cephalon ( CEPH) posted a second-quarter profit on higher-than-expected sales Monday after the close, as total company revenue increased 115% from the year-ago quarter.

Cephalon said it earned $14.4 million, or 25 cents a share, in the quarter, compared with a year-ago loss of $9.3 million, or 19 cents a share, excluding an extraordinary gain. Analysts polled by tracking firm Thomson Financial/First Call had been looking for 21 cents.

Despite the solid results, shares were recently down about 5% to $40.75 in premarket trading.

Total revenue was $120.7 million, up from $56.2 million last year and ahead of the consensus estimate of $111.68 million. Total product sales were $108.8 million, up from $44.3 million last year, led by sales of cancer painkiller ACTIQ, which increased 192% to $28.5 million.

Looking ahead, the company raised its full-year guidance on the "exceptionally strong sales of ACTIQ," saying it now expects to earn $1.08 to $1.10 a share on product sales of $430 million to $435 million. Previously, Cephalon had forecast $1.05 to $1.08 a share on sales of $415 million to $420 million.

For the third quarter, the company expects to earn 27 cents a share on sales of $110 million to $115 million.

First Call analysts are looking for $1.08 for the year and 27 cents for the third quarter.

If you liked this article you might like

Stocks to Watch: Ann Taylor Climbs, Electronics Sellers Drop

Stocks to Watch: Ann Taylor Climbs, Electronics Sellers Drop

Tough Month, Better Quarter for Retailers

Tough Month, Better Quarter for Retailers

AON Plunges on Accounting Issues, Earnings

AON Plunges on Accounting Issues, Earnings

Stocks to Watch: TiVo Climbs on Guidance, Cross Country Plunges

Stocks to Watch: TiVo Climbs on Guidance, Cross Country Plunges

Polo Posts Lower First-Quarter Results

Polo Posts Lower First-Quarter Results